May 22, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Repatha reduces CV events in patients who had PCI but no heart attack or stroke
In high-risk patients without prior heart attack or stroke who underwent percutaneous coronary intervention, evolocumab reduced risk for major adverse CV events compared with placebo, according to new data from the VESALIUS-CV trial. As Healio previously reported, in the main results of VESALIUS-CV, the PCSK9 inhibitor evolocumab (Repatha, Amgen) lowered risk for major adverse CV events by
742 words~3 min read
